AiCuris Anti-infective Cures AG

AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement

AiCuris Received 15 Million Euros Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS® for Prevention of CMV Infection in High-Risk Adult Kidney Transplant Recipients

AiCuris´ AiCubator Program Opens New Application Round for Innovative Projects with Focus on Treatment Options for Viral Infections in Immunocompromised Patients

AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of PREVYMIS® (letermovir) in Second Indication

AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients

AiCuris AG Announces Appointment of Larry Edwards as Chief Executive Officer and Formation of U.S. Subsidiary

AiCuris’ Licensing Partner MSD Demonstrates Efficacy in Phase 3 Study with PREVYMIS® for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation

AiCuris Anti-infective Cures AG: AiCuris´ innovation accelerator AiCubator calls for innovative proposals to propel anti-infective drug development in the third round

AiCuris nominates team of researchers from the Universitätsklinikum Erlangen as one of the 2022 winners of AiCubator Resident Status, a corporate innovation accelerator initiative

AiCuris appoints experienced business leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer

AiCuris eröffnet für seine internationale pivotale Phase-3-Studie mit Pritelivir zur Behandlung von Herpes-simplex-Virus-Infektionen bei immungeschwächten Patienten erste Studienzentren in Deutschland

AiCuris nominates Madam Therapeutics with its innovative peptide approach to fight AMR as the first winner of the AiCubator Resident Status in 2022

AiCuris erhält NRW-Förderung von insgesamt EUR 5,9 Mio. für die Entwicklung seines Corona-Virus-Programms zur Vorbeugung schwerer Symptome bei SARS-CoV-2-Infektionen

AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus

AiCuris announces expansion of its collaboration with Lysando with a focus on diabetic foot infections

AiCuris announces opening of second round of AiCubator corporate innovation accelerator initiative to propel anti-infective drug development

AiCuris starts pilot trial with proprietary immunomodulator AIC649, a unique therapy to prevent severe symptoms in SARS-CoV-2 infections

AiCuris starts its first pivotal clinical phase 3 trial with pritelivir for the treatment of HSV infections in immunocompromised subjects based on efficacy and safety data from a phase 2 trial

AiCuris AG Announces Dr. Stefan Oschmann, Former Merck CEO, to Chair the AiCuris Supervisory Board

AiCuris expands its Management with Prof. Dr. Hubert Trübel joining as Chief Medical Officer and the Appointment of Dr. Tamara Pfaff, Head of Preclinical Development, to the Management Team

AiCuris changes its legal form: AiCuris Anti-infective Cures GmbH becomes AiCuris AG

AiCuris selects three novel anti-infective treatment approaches as winners of the AiCubator Resident Status, a corporate innovative accelerator initiative

AiCuris to Present at the 39th Annual J.P. Morgan Healthcare Conference

AiCuris received approval from BfArM to initiate Compassionate Use Program for Pritelivir in Germany

AiCuris launches ‘PREP – Pandemic and Resistance Emergency Preparedness’ program at upcoming 4th AMR Conference

Royalty Pharma Acquires Partial Royalty Interest on Prevymis(TM) (Letermovir) from AiCuris Anti-infective Cures GmbH

AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients

AiCuris unterstützt das Land NRW bei der COVID-19 Ausbruchsbekämpfung in Schlachtbetrieben

AiCuris gets involved in the fight against Corona

AiCuris collaborates with myTomorrows to initiate an Early Access Program for Pritelivir